ETS factors facilitate AML1-ETO binding. (A) Venn diagram representing the overlap of ERG binding sites in K562-ERG cells not treated, or treated for 72 hours with dox. (B) ChIP-seq using K562-ERG cells expressing high levels (+ dox) or low levels (no dox) of ERG. Overview of the SPI1 AML1-ETO/ERG binding site in K562-ERG cells, transfected 24 hours before harvesting with AML1-ETO. Blue represents the AE ChIP-seq data; and yellow, the ERG data. (C) Overlap of DNAseI accessibility defined regions with ERG binding sites present before dox induction (ERG no dox) and ERG binding sites that appear after dox induction (ERG new). (D) Distribution of the ERG “no dox” and ERG “new” binding site locations relative to RefSeq genes. (E) Boxplot showing the tag density of AML1-ETO and ERG within “new” ERG binding sites in K562-ERG cells transfected with AML1-ETO and treated or untreated with dox.